NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.

Summary

Natural killer (NK) cells can kill a broad array of tumor cells in a non-major histocompatibility complex(MHC)-restricted manner. Adoptive transfer of NK may prolong the survival of patients with cancer. This study evaluates the efficacy and safety of NK cell-based immunotherapy for small-cell lung cancer (SCLC) after first-line chemotherapy. Half of the participants will receive autologous adoptive transfer of NK cells after the response from first-line chemotherapy, while the other half will be followed up in routine clinal practice.

Timeline

Start

2018-04-01

Primary completion

2019-06-01

Completion

2020-07-01

Drugs

Indications